Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? G.L. Daikos, A. Markogiannakis Clinical Microbiology.

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents

Vaccines for the elderly

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

L. S. Tzouvelekis, A. Markogiannakis, E. Piperaki, M. Souli, G. L

L. Boyanova Clinical Microbiology and Infection

Activity of imipenem against VIM-1 metallo-β-lactamase-producing Klebsiella pneumoniae in the murine thigh infection model G.L. Daikos, A. Panagiotakopoulou,

Gut bacterial microbiota and obesity

I.J. Schalk Clinical Microbiology and Infection

Approach to diagnosis of infective endocarditis

Herpes zoster in non-hospitalized children

Migrant health—a cause for concern?

Malaria in Europe: emerging threat or minor nuisance?

Clinical characteristics of Haemophilus influenzae meningitis in Denmark in the post- vaccination era T.I. Pedersen, M. Howitz, C. Østergaard Clinical.

Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome.

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

J.-P. Van geertruyden Clinical Microbiology and Infection

M. Giannella, B. Pinilla, J. A. Capdevila, J. Martínez Alarcón, P

R. Cantón Clinical Microbiology and Infection

P. Nordmann, L. Poirel Clinical Microbiology and Infection

Louis Pasteur, from crystals of life to vaccination

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

Klebsiella pneumoniae: development of a mixed population of carbapenem and tigecycline resistance during antimicrobial therapy in a kidney transplant.

Surveillance of Legionnaires’ disease in Austria

Do clinicians consider the results of the BinaxNOW Streptococcus pneumoniae urinary antigen test when adapting antibiotic regimens for pneumonia patients?

Impact of antibiotic restrictions: the pharmaceutical perspective

Vector control: a cornerstone in the malaria elimination campaign

Training for the infectious diseases speciality in Norway

G. Höffken Clinical Microbiology and Infection

B. Gordts Clinical Microbiology and Infection

Laboratory diagnosis and biosafety issues of biological warfare agents

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman Clinical.

Elements of design: the knowledge on which we build

S. Kurath, G. Halwachs-Baumann, W. Müller, B. Resch

Levofloxacin in the treatment of ventilator-associated pneumonia

R. Bitterman, M. Paul, D. Polak, Y. Geffen

Combating the spread of carbapenemases in Enterobacteriaceae: a battle that infection prevention should not lose P. Savard, T.M. Perl Clinical Microbiology.

Metagenomics and probiotics

Rapid acquisition of decreased carbapenem susceptibility in a strain of Klebsiella pneumoniae arising during meropenem therapy J. Findlay, A. Hamouda,

Previously unknown species of Aspergillus

Laboratory diagnosis of Clostridium difficile disease

Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy L.

The practice of travel medicine in Europe

T.M. File Clinical Microbiology and Infection

Long-term study of the frequency of Escherichia coli and Klebsiella pneumoniae isolates producing extended-spectrum β-lactamases L. Romero, L. López,

Harmonised monitoring of antimicrobial resistance in Salmonella and Campylobacter isolates from food animals in the European Union S. Bronzwaer Clinical.

Abstracts cont. Clinical Microbiology and Infection

Pandemic lineages of extraintestinal pathogenic Escherichia coli

Training in infectious diseases and tropical medicine in Britain

Current experience in treating invasive zygomycosis with posaconazole

Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan Y.-C. Hsieh, L.-Y. Chang, Y.-C. Huang, H.-C. Lin,

Vaccines for the elderly

Clinical infection services—the Leiden experience

Statin use and clinical outcomes among pneumonia patients

Clinical Microbiology and Infection

Bactericidal and synergistic activity of double-carbapenem regimen for infections caused by carbapenemase-producing Klebsiella pneumoniae A. Oliva, F.

K. Kaier, N.T. Mutters, U. Frank Clinical Microbiology and Infection

F.J. Pastor, J. Guarro Clinical Microbiology and Infection

The atypical pneumonias: clinical diagnosis and importance

J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin

Abstracts Clinical Microbiology and Infection

Modelling during an emergency: the 2009 H1N1 influenza pandemic

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

New patterns of HIV-1 resistance during HAART

G. Kahlmeter Clinical Microbiology and Infection

Impact of antibiotic restrictions: the patient's perspective

Comparative study of pediculicidal effect of medical plants

CMI readers' survey Clinical Microbiology and Infection

The future of diagnostic bacteriology

Presentation transcript:

Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? G.L. Daikos, A. Markogiannakis Clinical Microbiology and Infection Volume 17, Issue 8, Pages 1135-1141 (August 2011) DOI: 10.1111/j.1469-0691.2011.03553.x Copyright © 2011 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 1 Simulated concentration–time profiles of three different dosing regimens of meropenem. TI, traditional 30-min infusion; PI, prolonged 3-h infusion. Adapted from [35,45,47]. Clinical Microbiology and Infection 2011 17, 1135-1141DOI: (10.1111/j.1469-0691.2011.03553.x) Copyright © 2011 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 2 Simulated target attainment probabilities for 50% time above the MIC (50% T > MIC) of three different regiments of meropenem. TI, traditional 30-min infusion; PI, prolonged 3-h infusion. Adapted from [36]. Clinical Microbiology and Infection 2011 17, 1135-1141DOI: (10.1111/j.1469-0691.2011.03553.x) Copyright © 2011 European Society of Clinical Infectious Diseases Terms and Conditions